CA
HZNP

Crewe Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Crewe Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-123
Closed -$13.4K – 1032
2023
Q1 		$13.4K Hold
123
– – ﹤0.01% 497
2022
Q4 		$14K Sell
123
-100
-45% -$8.31K ﹤0.01% 484
2022
Q3 		$14K Buy
223
+19
+9% +$1.33K ﹤0.01% 577
2022
Q2 		$16K Buy
+204
New +$19.3K ﹤0.01% 484

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crewe Advisors's HZNP Position: Q2 2023 in Review

Crewe Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 123 shares — an estimated $13.4K sold.

Crewe Advisors first reported a position in HZNP in Q2 2022 and held it in 4 quarters. The position peaked at $16K in Q2 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Crewe Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 123 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $13.4K.
  • Crewe Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16K in Q2 2022.
  • 519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.